Literature DB >> 8144736

Subgingival distribution of A. actinomycetemcomitans in periodontitis.

J L Ebersole1, D Cappelli, M N Sandoval.   

Abstract

This investigation developed an experimental design that (1) detailed the distribution of A. actinomycetemcomitans in subgingival plaque related to the level of serum antibody to this pathogen; (2) used broad based subgingival plaque sampling to allow a definition of the distribution of A. actinomycetemcomitans infection in periodontitis patients; (3) described the distribution of A. actinomycetemcomitans serotypes in patients and within sites; and, (4) assessed how this infection impacted upon local clinical symptoms of disease. We noted a significant positive relationship between the level of IgG anti-A. actinomycetemcomitans antibody and the frequency of teeth infected until nearly 13 teeth demonstrated an infection. Furthermore, the results showed a generally negative relationship between the antibody level and the burden of A. actinomycetemcomitans in the infected sites. Interproximal sites associated with first molar teeth were the predominant sites for subgingival colonization; incisors were also frequently infected in this population. The first molar teeth also exhibited the greatest level of A. actinomycetemcomitans, while the incisors demonstrated a high level of A. actinomycetemcomitans in individual sites. The results clearly indicated the majority of the sites sampled were colonized by a single serotype of A. actinomycetemcomitans. We detected A. actinomycetemcomitans nearly 2 x times more frequently and a significant increase in the proportion of A. actinomycetemcomitans was found in samples obtained from teeth with bleeding on probing. The results also showed a significant trend for both pocket depth and attachment levels to be related to the presence and proportion of A. actinomycetemcomitans in the subgingival plaque. These findings detail the microbiological, immunological and clinical characteristics of a unique subset of periodontitis patients that appear to exhibit disease associated (caused?) with A. actinomycetemcomitans infection irrespective of clinical categorization. The results support a unique distribution of this microorganism in the subgingival ecology that is related to active host immune responses and clinical presentation of the tooth.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8144736     DOI: 10.1111/j.1600-051x.1994.tb00282.x

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  5 in total

1.  Antigenically diverse reference strains and autologous strains of Actinobacillus actinomycetemcomitans are equally efficient antigens in enzyme-linked immunosorbent assay analysis.

Authors:  Tiina Vilkuna-Rautiainen; Pirkko J Pussinen; Kimmo Mattila; Marja Vesanen; Heidi Ahman; Başak Doğan; Sirkka Asikainen
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

2.  Fine-tuned production of hydrogen peroxide promotes biofilm formation of Streptococcus parasanguinis by a pathogenic cohabitant Aggregatibacter actinomycetemcomitans.

Authors:  Dingyu Duan; Jessica A Scoffield; Xuedong Zhou; Hui Wu
Journal:  Environ Microbiol       Date:  2016-07-22       Impact factor: 5.491

3.  Polymicrobial interactions stimulate resistance to host innate immunity through metabolite perception.

Authors:  Matthew M Ramsey; Marvin Whiteley
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-21       Impact factor: 11.205

4.  Metabolite cross-feeding enhances virulence in a model polymicrobial infection.

Authors:  Matthew M Ramsey; Kendra P Rumbaugh; Marvin Whiteley
Journal:  PLoS Pathog       Date:  2011-03-31       Impact factor: 6.823

5.  CLINICAL AND MICROBIOLOGICAL ASSESSMENT OF NON-SURGICAL TREATMENT OF CHRONIC PERIODONTITIS IN CONTROLLED AND UNCONTROLLED TYPE 2 DIABETIC PATIENTS.

Authors:  Jelena Mirnić; Milanko Đurić; Nađa Nikolić; Tanja Veljović; Ivana Gušić; Đorđe Petrović; Jelena Milašin
Journal:  Acta Clin Croat       Date:  2022-02       Impact factor: 0.932

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.